Nes­san Berming­ham re­turns to VC life; Sanofi's gener­ics unit gets two in­dus­try bid­ders in EMS and Tor­rent Phar­ma

→ Now that In­tel­lia Ther­a­peu­tics $INTL is sail­ing steadi­ly to­ward its first hu­man stud­ies with Ab­b­Vie vet John Leonard at the helm, Nes­san Berming­ham will of­fi­cial­ly re-join At­las Ven­ture as a ven­ture part­ner. Berming­ham had been CEO of the At­las-backed CRISPR/Cas-9 up­start (which he co-found­ed) for four years, lead­ing the com­pa­ny from seed in­vest­ment through an IPO to clin­i­cal de­vel­op­ment. Back in his ven­ture cap­i­tal­ist shoes, he will be scout­ing for new biotechs for the At­las plat­form.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER